On “The P2 Receptors and Congenital Platelet Function Defects” (Semin Thromb Hemost 2005;31:168-173)

I read with interest the manuscript by Cattaneo.[1] Within the context of the discussion on platelet ADP receptors, the author states, “P2Y₁₂ is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel, which are already used in clinical practice, and the AIDS-related complex compounds, one of which is currently under evaluation…” (emphasis added). The author sites the work by Humphries[2] in support.

The referenced compound, AR-C69931MX, was so denoted because it was developed, in part, by Astra Research-Charnwood. The molecule is an ADP analogue and is not associated with either HIV or the constellation of symptoms commonly referrred to as the AIDS-related complex.

REFERENCES

• 1 Cattaneo M. The P2 receptors and congenital platelet function defects.  Semin Thromb Hemost. 2005;  31 168-173
• 2 Humphries R G. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials.  Haematologica. 2000;  85 66-72